Fellows are encouraged to spend a total of 8 to 12 months in the second and third years doing a research project. The faculty's research interests are diverse and offer a wide array of opportunities in both developmental therapeutics and bench research. Ongoing clinical studies include monoclonal antibodies as therapeutic agents; phase I/II trials of new chemotherapeutic agents; and pharmacokinetics studies of drug levels in blood and tumors. Basic research includes the areas of molecular biology of tumor invasiveness and oncogenesis, hemostasis and thrombosis, cellular proliferation and mechanisms of cell activation, gene-therapy strategies, HIV-associated disorders, and membrane ion transport. Funding for research includes grants from the National Institutes of Health, the American Heart Association, the American Cancer Society, and various drug companies.